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ABSTRACT 
Background: For patients with atrial fibrillation (AF), a comprehensive care 
approach based on the “Atrial fibrillation Better Care” (ABC) pathway can reduce the 
occurrence of adverse outcomes. The aim of this paper was to investigate if an 
approach based on the ABC pathway is associated with a reduced risk of adverse 
events in ‘clinically complex’ AF patients, including those with multiple co-morbidities, 
polypharmacy and prior hospitalizations. 
Methods and Results: We performed a post-hoc analysis of the Atrial Fibrillation 
Follow-up Investigation of Rhythm Management (AFFIRM) trial.  The principal 
outcome was the composite of all-cause hospitalization and all-cause death. 
An integrated care approach (ABC group) was used in 3.8%, 4.0% and 4.8% in 
multimorbidity, polypharmacy and hospitalized groups, respectively. In all ‘clinically 
complex’ groups, the cumulative risk of the composite outcome was significantly 
lower in patients managed consistent with the ABC pathway vs. non-ABC pathway-
adherent (all p<0.05). Cox regression analysis showed a reduction of composite 
outcomes in ABC pathway-adherent vs. non-ABC pathway-adherent for multi-
morbidity (hazard ratio [HR]: 0.61, 95% confidence interval [CI]: 0.44-0.85), 
polypharmacy (HR: 0.68, 95% CI: 0.47-1.00) and hospitalization (HR: 0.59, 95% CI: 
0.42-0.85) groups. Secondary analyses showed that the higher number of ABC 
criteria fulfilled the larger associated reduction in relative risk, even for secondary 
outcomes considered. 
Conclusions: Use of an ABC consistent pathway is associated with fewer major 
adverse events in patients with AF who have multiple co-morbidities, use of 
polypharmacy and prior hospitalization. 
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CLINICAL PERSPECTIVE 
 
What is new? 
• In this post-hoc analysis, we demonstrated that in clinically complex atrial 
fibrillation (AF) patients (i.e. those presenting with multimorbidity, polypharmacy 
and presenting with a recent hospitalization), a clinical management adherent to 
the ‘Atrial fibrillation Better Care’ (ABC) pathway, an approach to streamline the 
integrated care in AF, is associated with a reduction in major adverse events risk. 
 
What are the clinical implications? 
• In high-risk group of AF patients, such as those more clinically complex, the 
application of a more integrated, holistic, clinical approach that would take 
account of all the aspects related to the general and specific management of the 
disease would entail a significant and substantial reduction of all major adverse 
outcomes.  
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NON-STANDARD ABBREVIATIONS 
ABC= Atrial Fibrillation Better Care 
AFFIRM= Atrial Fibrillation Follow-up Investigation of Rhythm Management r  
 5 
INTRODUCTION 
Patients affected with atrial fibrillation (AF) are at high risk for cardiovascular and 
non-cardiovascular death1–6. This risk is associated with multiple co-morbidities7,8, 
polypharmacy6,9,10 and prior hospitalization11,12 , all features that characterize the 
‘clinically complex’ patient. 
 
Evidence has emerged indicating that an integrated or holistic management 
approach in patients with AF can reduce mortality associated with AF13. These data, 
together with the need to reduce major adverse events in AF patients beyond just 
the risk of ischemic stroke, has inspired new thinking regarding a multifaceted 
approach to AF management14–16. The Atrial fibrillation Better Care (ABC) pathway 
has been proposed to streamline implementation of an integrated approach to 
managing patients with AF16. 
 
The ABC pathway has three main pillars: ‘A’ Avoid stroke (with Anticoagulants); ‘B’ 
Better symptom management, with patient-centred decisions on rate or rhythm 
control; ‘C’ Cardiovascular and Comorbidity risk optimisation16. Thus far, 
retrospective analyses have shown that management resembling the ABC pathway 
has been associated with reduction in AF-related clinical outcomes17–19. In a post-
hoc analysis derived from the Atrial Fibrillation Follow-up Investigation of Rhythm 
Management (AFFIRM) trial, we previously showed how a clinical approach based 
on ABC pathway was associated with reduction in risk for major bleeding, all-cause 
death, cardiovascular (CV) death, first hospitalization, first CV hospitalization and 
multiple hospitalizations17. 
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Here, we investigate if an  approach based on the ABC pathway is associated with 
reduced risk of adverse events in three prespecified subgroups of ‘clinically complex’ 
AF patients at high risk for all-cause death and other adverse outcomes, including 
those with multiple co-morbidities, those taking multiple drugs (polypharmacy) and 
those hospitalized when AF was diagnosed. 
 
METHODS 
The authors declare that all supporting data and methods used to derive the results 
and the related findings are available within the article. 
 
We considered patients enrolled in the AFFIRM trial20,21. The AFFIRM trial was 
approved by the University of Missouri Institutional Review Board (IRB); the 
database was obtained from the National Institute of Health. The IRB for every 
participating centre approved the study protocol and all patients entered the study 
after providing written informed consent. The study was performed according to the 
EU Note for Guidance on Good Clinical Practice CPMP/ECH/135/95 and the 
Declaration of Helsinki. 
 
Implementation of the ABC pathway in the AFFIRM trial cohort has been described 
in detail elsewhere17. In brief, the ‘A’ criterion was fulfilled if the patient had a time in 
therapeutic range ≥70%; the ‘B’ criterion was fulfilled if the patient presented with 2 
or less symptoms; the ‘C’ criterion was fulfilled if the patient were properly managed 
for the concomitant CV comorbidities (hypertension, coronary artery disease, 
peripheral artery disease, previous stroke/transient ischemic attack, heart failure)17.  
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We defined three groups of ‘clinically complex’ patients, deemed at high risk for 
adverse AF-related outcomes: i) Multimorbidity group: if the patient  had two or 
more concomitant conditions22, among the 11 listed in the AFFIRM case report form 
(myocardial infarction, heart failure, hypertension, cardiomyopathy, valvular heart 
disease, congenital heart disease, previous stroke/transient ischemic attack, 
peripheral arterial disease, diabetes, hepatic/renal disease, pulmonary disease); ii) 
Polypharmacy group: if the patient  used 5 or more drugs, as reported in a 
previous paper from the same cohort6; iii) Hospitalization group: if the patient  was 
hospitalized at the time of the index AF event, as was originally included in the 
AFFIRM study. 
 
Study Outcomes 
The primary outcome considered was a composite of all-cause hospitalization and 
all-cause death. We separately considered all-cause hospitalization and all-cause 
death as independent outcomes. We also considered occurrence of cardiovascular 
events, defined as stroke, major bleeding, CV hospitalization or CV death, as 
additional outcomes. Finally, we considered occurrence of any clinical event among 
those described above as a study outcome. All the specific clinical events (i.e. not 
those composite) were adjudicated centrally, according to the original study 
protocol20.  
 
Statistical Analysis 
All continuous variables were reported as median and interquartile range (IQR). 
Categorical variables were expressed as counts and percentages and compared 
using the chi-square test. 
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Cumulative incidence of adverse events is shown using Kaplan-Meier curves, and 
compared across the groups with the Log-Rank test. Cox regression was used to 
assess the association between the use of integrated care adherent to the ABC 
pathway and the occurrence of outcomes. Covariates considered for adjustment 
were age, sex, diabetes mellitus, hepatic/renal disease, pulmonary disease, first AF 
episode, and use of aspirin, and were implemented in the various models as 
reported specifically in the Tables and Figures.  
 
The main analyses included comparisons between the ABC pathway consistent 
group vs. the non-ABC pathway group. A secondary analysis examined the 
relationship between the total number of ABC pathway criteria fulfilled and 
occurrence of the study outcomes. Finally, a sensitivity analysis examined the 
degree of overlap between the three subgroups and the impact of the ABC adherent 
management. A two-sided p-value <0.05 was considered statistically significant. All 
analyses were performed using SPSS v. 25.0 (IBM, NY, USA. 
 
RESULTS 
From the original AFFIRM cohort, a total of 3169 (78.0%) patients were available for 
this analysis17. Baseline characteristics of this cohort are reported in Table 1. Median 
[IQR] age was 70 [65-76] years, 1237 (39.0%) were female, median [IQR] CHA2DS2-
VASc score was 3 [2-4] and median [IQR] time in therapeutic range was 67.9% 
(51.5-81.0%). Of this cohort, 222 (7.0%) were managed consistent with the ABC 
pathway17.  
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The multimorbidity group comprised 1723 (54.4%) patients, while 1222 (38.6%) were 
included in the polypharmacy group and 1360 (42.9%) in the hospitalization group. 
Baseline characteristics for the three groups were summarised in Table 1. Median 
age was similar between the groups, with a slightly lower prevalence of females in 
the multimorbidity group. CHA2DS2-VASc score was numerically higher in the 
multimorbidity group compared to the overall cohort and the other subgroups. ABC 
pathway consistent management was found in 66 (3.8%) in the multimorbidity group, 
49 (4.0%) in the polypharmacy group and in 65 (4.8%) for the hospitalization group. 
 
Follow-Up Analysis 
In the multimorbidity group, after a median [IQR] 3.63 [2.73-4.54] years of follow-up, 
there were 1238 composite outcome events (37.8 per 100 patient-years), 1185 
hospitalization events (36.2 per 100 patient-years), 262 all-cause death (4.21 per 
100 patient-years), 855 cardiovascular events (20.3 per 100 patient-years) and a 
total of 1245 ‘any event’ outcomes (38.3 per 100 patient-years). Event rates for the 
non-ABC group was significantly higher than the ABC group for all outcomes 
considered [Figure 1, Panel A]. 
 
In the polypharmacy group, after a median [IQR] 3.59 [2.73-4.49] years of follow-up, 
a similar rate of events was evident, except for all-cause death which was 
numerically lower than in the multimorbidity group. There were 865 composite 
outcome events (37.7 per 100 patient-years), 833 hospitalizations  (36.3 per 100 
patient-years), 165 deaths (3.76 per 100 patient-years), 599 cardiovascular events 
(20.5 per 100 patient-years) and a total of 870 ‘any event’ outcomes (38.4 per 100 
patient-years). The overall rate of outcomes was higher in non-ABC pathway-
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adherent group than in ABC pathway-adherent group (see Figure 1 Legend), except 
for all-cause death (p=0.123) [Figure 1, Panel B]. 
 
A similar rate of events was reported in the hospitalization group, with 967 composite 
outcome events (37.0 per 100 patient-years), 929 recurrent hospitalization (35.5 per 
100 patient-years), 187 deaths (3.66 per 100 patient-years), 687 cardiovascular 
events (20.7 per 100 patient-years) and a total of 972 ‘any event’ outcomes (37.5 per 
100 patient-years). Similar to the results from the other two groups, non-ABC 
pathway adherent patients reported a higher rate of all outcomes under 
consideration (all p<0.001), except for all-cause death; mortality was numerically 
lower but did not reach statistical significance (p=0.068) [Figure 1, Panel C]. 
 
Kaplan-Meier curves for the composite outcome showed that patients managed with 
ABC pathway-adherent care had a lower cumulative risk in all 3 ‘clinically complex’ 
patient groups [Figure 2, Panels A, B, C]. 
 
Cox Regression Analysis 
A Cox regression analysis was performed (Table 2). In the multimorbidity group, 
ABC clinical management was associated with a reduction in risk for the composite 
outcome (hazard ratio [HR]: 0.61, 95% confidence interval [CI]: 0.44-0.85, p=0.004), 
with a significant reduction in relative risk for all the other outcomes considered, in 
particular, for all-cause death (HR: 0.23, 95% CI: 0.06-0.94, p=0.041) (Table 2). 
 
In the polypharmacy group, adjusted risk reduction for the composite outcome 
approached statistical significance (HR: 0.68, 95% CI: 0.47-1.00, p=0.053) (Table 2). 
 11 
A reduction in risk was found for any event outcome (HR: 0.68, 95% CI: 0.46-0.99, 
p=0.045), but no significant difference was found for all-cause death (Table 2). 
 
Results similar to those in the multimorbidity group were observed for patients 
hospitalized at the time of the index event, with a significant reduction in the risk of 
the composite outcome and other secondary outcomes, but no significant difference 
in the risk of all-cause death was found (Table 2). 
 
Secondary Analyses 
A secondary analysis was performed to compare the number of ABC pathway 
criteria fulfilled vs. no ABC pathway criteria fulfilled [Figure 3].  In the multimorbidity 
group, there was a progressively lower risk of outcomes according to the increasing 
number of ABC criteria fulfilled [Figure 3, Panel A], with the higher risk reduction 
obtained when all 3 ABC criteria are fulfilled compared to no ABC criteria.  
 
In the polypharmacy group a similar relationship between the number of ABC criteria 
and occurrence of outcomes was found, albeit with a slightly lower magnitude than in 
the multimorbidity group [Figure 3, Panel B]. For the occurrence of the all-cause 
death, a significant reduction in risk was associated with 1 ABC criterion (HR: 0.68, 
95% CI: 0.48-0.94) or 2 ABC criteria fulfilled (HR: 0.51, 95% CI: 0.31-0.83), however, 
when all 3 ABC criteria were fulfilled there was a non-statistically significant 
reduction, with wide 95%CI (HR: 0.36, 95% CI: 0.12-1.18) [Figure 3, Panel B].  
 
In the hospitalization group, a similar reduction in the risk of major adverse events 
was evident with an increasing number of ABC criteria fulfilled, with the strongest 
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reduction in risk for the composite outcome when all 3 ABC criteria were fulfilled 
(HR: 0.45, 95% CI: 0.31-0.65).  In all three “clinically complex” patients’ subgroups, 
increasing number of ABC pathway criteria fulfilled were associated with a 
progressively lower risk for the occurrence of ‘any event’, with the exception of the 
outcome of all-cause death in the polypharmacy group. 
 
Sensitivity Analysis 
We examined how much the three subgroups overlapped and what was the impact of 
ABC adherent management in reducing the occurrence of outcomes. Among the 3169 
patients included in this analysis, only 740 (23.4%) were not included in any of the 3 
clinically complex subgroups, while among the remaining 2429 patients, 1058 (43.6%) 
were included in only one subgroup, 866 (35.7%) were included in two subgroups and 
493 (20.8%) were included in all 3 subgroups.  
 
The prevalence of ABC pathway adherent group decreased progressively from those 
included in only one subgroup to those included in all the 3 subgroups (7.4% vs. 3.8% 
vs. 2.4%, p<0.001). Given the low numbers, we only considered the occurrence of the 
primary outcome. Among those included in ≥ 2 subgroups, patients managed adherent 
to ABC pathway had a lower rate of composite outcome (57.8% vs. non-ABC 
adherent, 74.0%; p=0.015). After adjustment, the Cox regression analysis 
demonstrated that ABC pathway adherence among those included in ≥ 2 subgroups 
was associated to a lower risk of the primary outcome (HR: 0.60, 95% CI: 0.44-0.96).  
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DISCUSSION 
In this post-hoc subgroup analysis derived from the AFFIRM trial, we showed that in 
clinically complex patient subgroups (i.e. multimorbidity, polypharmacy, 
hospitalization), management with an approach consistent with the one proposed by 
the ABC pathway, that streamline the approach to AF patients care, was associated 
with reduction in the composite outcome of all-cause hospitalization and all-cause 
death in all the three groups considered. Management consistent with the ABC 
pathway was associated with reduction of ‘any event’ outcome for those clinical 
events considered. Further, an increasing number of ABC criteria fulfilled was 
associated with a progressively larger reduction in risk for most of the outcomes 
considered. Lastly, even amongst patients having ≥2 clinical complex characteristics, 
the adherence to ABC pathway is still associated with a lower risk of the composite 
outcome, reinforcing the separate evidence coming from the 3 clinical subgroups. 
 
The impact of the three clinical subgroups (i.e. multimorbidity, polypharmacy, 
hospitalization) in determining an increased risk in major adverse events have been 
previously described6–12,23. For the presence of multimorbidity, several observational 
and randomized controlled trials have shown an increased risk for all major adverse 
events relevant to AF patients, in particular all-cause death7,8,23. Similarly, an 
increased risk of cardiovascular events and death is evident for AF patients reporting 
polypharmacy6,9,10 and an increased risk of death in hospitalized AF patients11,12 
were reported. In all these conditions, an increased rate of events was described, 
with an increased association with risk of events that was found to be independent of 
other clinical characteristics. Given the increased complexity and the higher risk of 
major adverse events in those with the described clinical features, an approach 
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consistent with the ABC pathway may be beneficial. Indeed, a large group of patients 
were included in at least two of the subgroups and hence, had even greater clinical 
complexity. 
 
Streamlining decision-making to facilitate management of clinically complex patients 
with AF starting with primary care and linking with secondary care (including 
cardiologist and non-cardiologists) may improve outcomes. The ABC pathway has 
been proposed as a simple and pragmatic approach to streamline and  integrate 
care16. Thus far, the ABC pathway has been tested indirectly, but it appears to 
reduce major adverse events in patients with AF17–19. Prior studies have assessed 
several clinical settings and patients’ characteristics including the overall AFFIRM 
cohort17–19. 
 
In our study, together with the previous analysis on the ABC pathway in AFFIRM17, 
we found a low percentage of patients treated as fully adherent to the ABC pathway 
compared to other studies18,19. In a prospective Italian observational cohort, for 
example, management adherent with the ABC pathway was associated with a 56% 
risk reduction for a composite outcome of cardiovascular events18. Similarly, in a 
population-based nationwide cohort, there was a significant reduction (~15%) in all 
adverse outcomes with ABC pathway-adherent management19. Considering the time 
of the AFFIRM study enrollment (>15 years ago), it is possible that a clinical 
management based on a single-disease approach was more common in the past, 
compared to current practice, which holistic and integrated management is more 
used. 
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In the present post-hoc analysis, even in high risk subgroups, where the risk of 
adverse events is high, use of an ABC pathway approach was associated with fewer 
AF-related outcomes. The adjudicated outcomes of hospitalization and all-cause 
death were reduced in all three subgroups. The risk for hospitalization (considered 
as a single outcome) was also reduced with similar magnitude. Nonetheless, we may 
be underpowered to assess reduction in all-cause death in the polypharmacy and 
hospitalization groups. 
 
Our secondary analysis showed that risk was progressively lowered with a 
progressively higher numbers of ABC criteria fulfilled. This trend was also evident for 
all-cause death in the polypharmacy and hospitalization groups. However, the low 
number of events in the fully ABC pathway-adherent group is a limitation; however, 
the consistency of results in the patients with even higher clinical complexity 
reinforces the idea that more complex patient is much more likely to get a beneficial 
effect from a comprehensive and integrated approach to AF care.  Indeed, utilization 
of the ABC pathway was associated with reduction in ‘any clinical event’ amongst 
these clinically complex patients further emphasizes the importance of improving the 
overall management of AF patients comprehensively, beyond thromboembolic risk24. 
 
Limitations 
The post-hoc nature, the modest number of subjects in the ABC compliant groups 
compared to the overall cohort (which limits the reliability of Kaplan-Meier analysis) 
and the relatively aged dataset are limitations to this analysis. Since the AFFIRM 
study is an old clinical trial, this could limit the generalizability of our results, given 
the changes in AF management practices that have occurred in the last 15 years. 
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Also, other general management aspects of AF patients (such as weight 
management, evaluation/management of sleep apnoea, etc) were not routinely 
assessed at the time of the AFFIRM study and were not reported in the trial dataset. 
The AFFIRM trial compared rhythm vs rate) control, but this was not the objective of 
the present study which focused on ‘better symptom’ management overall (even 
within the heart failure subgroup, where rhythm control with catheter ablation has 
been beneficial compared to only drug therapy25).  Nonetheless, we believe that the 
AFFIRM study design, which included patients with significant risk factors, still gives 
a good representation of the ‘typical’ AF population.  
 
Conversely, the adjudicated outcomes and the largely proved reliability of the 
AFFIRM database makes this hypothesis generating analysis reliable. Indeed, these 
results, supported by previous evidence, encourages use of an ABC pathway-
adherent approach, to streamline and integrate care in clinically complex patients 
with AF. 
 
CONCLUSION 
Management of AF by an ABC consistent pathway is associated with reduction in 
major adverse events in clinically complex AF patients, including those with 
multimorbidity, polypharmacy and prior hospitalization. These exploratory findings 
need further confirmation in larger, more contemporary studies. 
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Table 1: B
aseline C
haracteristics of the O
verall C
ohort and C
linically C
om
plex Subgroups 
 
O
verall C
ohort 
N
= 3169 
M
ultim
orbidity 
N
= 1723 
Polypharm
acy 
N
= 1222 
H
ospitalization 
N
= 1360 
A
ge years, m
edian [IQ
R
] 
70 [65-76] 
70 [64-76] 
71 [65-76] 
70 [65-76] 
Fem
ale sex, n (%
) 
1237 (39.0) 
656 (38.1) 
530 (43.4) 
586 (43.1) 
H
ypertension, n (%
) 
2243 (70.8) 
1445 (83.9) 
1009 (82.6) 
979 (72.0) 
D
iabetes M
ellitus, n (%
) 
625 (19.7) 
576 (33.4) 
325 (26.6) 
306 (22.5) 
Sm
oking, n (%
) 
378 (11.9) 
256 (14.9) 
167 (13.7) 
179 (13.2) 
C
oronary A
rtery D
isease, n (%
) 
1164 (36.7) 
873 (50.7) 
653 (53.4) 
567 (41.7) 
M
yocardial Infarction, n (%
) 
523 (16.5) 
489 (28.4) 
333 (27.3) 
262 (19.3) 
Peripheral A
rterial D
isease, n (%
) 
202 (6.4) 
190 (11.0) 
112 (9.2) 
103 (7.6) 
Stroke/TIA
, n (%
) 
431 (13.6) 
379 (22.0) 
195 (16.0) 
235 (17.3) 
H
eart Failure, n (%
) 
684 (21.6) 
659 (38.2) 
442 (36.2) 
393 (28.9) 
Valvular H
eart D
isease, n (%
) 
401 (12.7) 
354 (20.5) 
192 (15.7) 
177 (13.0) 
H
epatic/R
enal D
isease, n (%
) 
158 (5.0) 
149 (8.6) 
88 (7.2) 
87 (6.4) 
Pulm
onary D
isease, n (%
) 
427 (13.5) 
375 (21.8) 
199 (16.3) 
226 (16.6) 
First A
F Episode, n (%
) 
1016 (33.1)* 
610 (36.5)† 
419 (34.3) ‡ 
556 (43.0)# 
U
se of A
spirin, n (%
) 
772 (24.4) 
468 (27.2) 
462 (37.8) 
413 (30.4) 
C
H
A
2 D
S
2 -VA
Sc, m
edian [IQ
R
] 
3 [2-4] 
4 [3-4] 
3 [2-4] 
3 [2-4] 
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TTR
 %
, m
edian [IQ
R
] 
67.9 (51.5-81.0) 
65.9 [48.1-80.0] 
67.1 [49.3-80.8] 
63.4 [46.3-79.2] 
A
B
C
 pathw
ay adherent patients,  
n (%
) 
222 (7.0) 
66 (3.8) 
49 (4.0) 
65 (4.8) 
Follow
-U
p Tim
e years, m
edian 
[IQ
R
] 
3.70 [2.82-4.59] 
3.63 [2.73-4.54] 
3.59 [2.73-4.49] 
3.78 [2.89-4.67] 
Legend: *available for 3067 patients; †available for 1673 patients; ‡available for 1222 patients; #available for 1292 patients; ABC
= 
atrial fibrillation better care; AF= atrial fibrillation; ABC
= atrial fibrillation better care; IQ
R
= interquartile range; TIA= transient 
ischem
ic attack; TTR
= tim
e in therapeutic range. 
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Table 2: Relationship between Integrated Care and Major Adverse Events 
 ABC adherent vs. Non-ABC adherent 
 Univariate Analysis Multivariate Analysis 
 HR (95% CI) p HR (95% CI) p 
Multimorbidity*     
Composite Outcome 0.60 (0.43-0.83) 0.002 0.61 (0.44-0.85) 0.004 
Hospitalization 0.61 (0.44-0.85) 0.004 0.62 (0.45-0.87) 0.006 
All-Cause Death 0.22 (0.06-0.88) 0.033 0.23 (0.06-0.94) 0.041 
Cardiovascular Events 0.53 (0.34-0.83) 0.005 0.54 (0.35-0.84) 0.007 
Any Event 0.59 (0.42-0.82) 0.002 0.60 (0.43-0.84) 0.003 
Polypharmacy†     
Composite Outcome 0.67 (0.46-0.98) 0.038 0.68 (0.47-1.00) 0.053 
Hospitalization 0.68 (0.45-0.99) 0.042 0.69 (0.46-1.01) 0.058 
All-Cause Death 0.50 (0.16-1.56) 0.23 0.49 (0.16-1.54) 0.22 
Cardiovascular Events 0.66 (0.41-1.06) 0.087 0.67 (0.41-1.08) 0.099 
Any Event 0.66 (0.45-0.97) 0.033 0.68 (0.46-0.99) 0.045 
Hospitalization‡     
Composite Outcome 0.59 (0.41-0.83) 0.003 0.59 (0.42-0.85) 0.004 
Hospitalization 0.57 (0.40-0.82) 0.003 0.58 (0.40-0.84) 0.004 
All-Cause Death 0.51 (0.19-1.36) 0.18 0.49 (0.18-1.33) 0.16 
Cardiovascular Events 0.48 (0.30-0.76) 0.002 0.48 (0.30-0.77) 0.002 
Any Event 0.58 (0.41-0.83) 0.002 0.59 (0.41-0.84) 0.003 
Legend: *Multivariate analysis adjusted for age, sex, first AF episode, use of aspirin; 
†Multivariate analysis adjusted for age, sex, first AF episode, diabetes mellitus, 
hepatic/renal disease, pulmonary disease; ‡Multivariate analysis adjusted for age, 
sex, first AF episode, diabetes mellitus, hepatic/renal disease, pulmonary disease, 
use of aspirin; ABC= atrial fibrillation better care; AF= atrial fibrillation. 
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FIGURE LEGENDS 
 
Figure 1: Rate of Major Adverse Events according to Clinically Complex 
Subgroups 
Legend: Panel A) Multimorbidity: Composite Outcome: p=0.001, Hospitalization: 
p=0.005, All-Cause Death: p=0.005, Cardiovascular Events: p=0.001, Any Event: 
p=0.001; Panel B) Polypharmacy: Composite Outcome: p=0.014, Hospitalization: 
p=0.021, All-Cause Death: p=0.123, Cardiovascular Events: p=0.041, Any Event: 
p=0.011; Panel C) Hospitalization: Composite Outcome: p<0.001, Hospitalization: 
p<0.001, All-Cause Death: p=0.068, Cardiovascular Events: p<0.001, Any Event: 
p<0.001; ABC= atrial fibrillation better care. 
 
Figure 2: Kaplan-Meier Curves for Any Event according to Clinically Complex 
Subgroups 
Legend: Panel A) Multimorbidity; Panel B) Polypharmacy; Panel C) Hospitalization; 
Solid Line= ABC Adherent; Dashed Line= Non-ABC Adherent; ABC= atrial fibrillation 
better care. 
 
Figure 3: Relationship between Number of ABC Criteria and Major Adverse 
Events according to Clinically Complex Subgroups 
Legend: Multimorbidity group analysis adjusted for age, sex, first AF episode, use of 
aspirin; Polypharmacy group analysis adjusted for age, sex, first AF episode, 
diabetes mellitus, hepatic/renal disease, pulmonary disease; Hospitalization group 
analysis adjusted for age, sex, first AF episode, diabetes mellitus, hepatic/renal 
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disease, pulmonary disease, use of aspirin; ABC= atrial fibrillation better care; CI= 
Confidence Interval; HR= Hazard Ratio. 
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